{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:39:57Z","timestamp":1792784397274,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"},{"name":"Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority","award":["HHSO100201300011C"],"award-info":[{"award-number":["HHSO100201300011C"]}],"id":[{"id":"https:\/\/ror.org\/029y69023","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40121-022-00706-9","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T14:04:29Z","timestamp":1666361069000},"page":"2297-2310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants"],"prefix":"10.1007","volume":"11","author":[{"given":"Caroline","family":"Perry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcy","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Scangarella-Oman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Tiffany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Janmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"706_CR1","doi-asserted-by":"publisher","first-page":"175628721983217","DOI":"10.1177\/1756287219832172","volume":"11","author":"M Medina","year":"2019","unstructured":"Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019;11:1756287219832172.","journal-title":"Ther Adv Urol"},{"key":"706_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrurol.2010.190","volume":"7","author":"B Foxman","year":"2010","unstructured":"Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7:653\u201360.","journal-title":"Nat Rev Urol"},{"key":"706_CR3","volume-title":"Urological infections","author":"G Bonkat","year":"2020","unstructured":"Bonkat G, Bartoletti R, Bruy\u00e8re F, et\u00a0al. Urological infections. Arnhem: EAU Guidelines Office; 2020."},{"key":"706_CR4","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, Hooton TM, Naber KG, et\u00a0al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103\u201320.","journal-title":"Clin Infect Dis"},{"key":"706_CR5","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/cid\/ciab560","volume":"73","author":"KS Kaye","year":"2021","unstructured":"Kaye KS, Gupta V, Mulgirigama A, et\u00a0al. Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011\u20132019: rising ESBL strains and impact on patient management. Clin Infect Dis. 2021;73:1992\u20139.","journal-title":"Clin Infect Dis"},{"key":"706_CR6","unstructured":"World Health Organization. Ten threats to global health in 2019. https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019. Accessed 1 Mar 2022."},{"key":"706_CR7","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic Resistance Threats in the United States, 2019","author":"Centers for Disease Control and Prevention","year":"2019","unstructured":"Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta: US Department of Health and Human Services; 2019."},{"key":"706_CR8","volume-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva: World Health Organization; 2017."},{"key":"706_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1128\/CMR.00125-13","volume":"27","author":"MH Nicolas-Chanoine","year":"2014","unstructured":"Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev. 2014;27:543\u201374.","journal-title":"Clin Microbiol Rev"},{"key":"706_CR10","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/. Accessed 7 Oct 2021."},{"key":"706_CR11","doi-asserted-by":"publisher","first-page":"ofab380","DOI":"10.1093\/ofid\/ofab380","volume":"8","author":"TP Lodise","year":"2021","unstructured":"Lodise TP, Henriksen AS, Hadley T, Patel N. US-focused conceptual health care decision-analytic models examining the value of pivmecillinam relative to current standard-of-care agents among adult patients with uncomplicated urinary tract infections due to Enterobacterales. Open Forum Infect Dis. 2021;8:ofab380.","journal-title":"Open Forum Infect Dis"},{"key":"706_CR12","unstructured":"Health Canada. Selexid product information. https:\/\/health-products.canada.ca\/dpd-bdpp\/info.do?lang=en&code=94365. Accessed 7 Oct 2021."},{"key":"706_CR13","unstructured":"The Pew Charitable Trusts. Tracking the global pipeline of antibiotics in development, March 2021. https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/issue-briefs\/2021\/03\/tracking-the-global-pipeline-of-antibiotics-in-development. Accessed 7 Oct 2021."},{"issue":"Suppl 1","key":"706_CR14","doi-asserted-by":"publisher","first-page":"S798","DOI":"10.1093\/ofid\/ofab466.1625","volume":"8","author":"AS Henriksen","year":"2021","unstructured":"Henriksen AS, Nicolle L, Das AF. Impact of 2019 US Food and Drug Administration (FDA) guidance on developing drugs for urinary tract infection (UTI) on the perceived efficacy of antibiotics for the treatment of uncomplicated UTI (uUTI) [abstract 1433]. Open Forum Infect Dis. 2021;8(Suppl 1):S798.","journal-title":"Open Forum Infect Dis"},{"key":"706_CR15","volume-title":"Uncomplicated urinary tract infections: developing drugs for treatment guidance for industry","author":"US Food and Drug Administration","year":"2019","unstructured":"US Food and Drug Administration. Uncomplicated urinary tract infections: developing drugs for treatment guidance for industry. Beltsville: US Department of Health and Human Services; 2019."},{"key":"706_CR16","unstructured":"European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, Rev 3. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf. Accessed 1 Feb 2022."},{"key":"706_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nature09197","volume":"466","author":"BD Bax","year":"2010","unstructured":"Bax BD, Chan PF, Eggleston DS, et\u00a0al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature. 2010;466:935\u201340.","journal-title":"Nature"},{"key":"706_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","volume":"5","author":"EG Gibson","year":"2019","unstructured":"Gibson EG, Bax B, Chan PF, Osheroff N. Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase. ACS Infect Dis. 2019;5:570\u201381.","journal-title":"ACS Infect Dis"},{"key":"706_CR19","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1128\/AAC.02820-15","volume":"60","author":"DJ Biedenbach","year":"2016","unstructured":"Biedenbach DJ, Bouchillon SK, Hackel M, et\u00a0al. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother. 2016;60:1918\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"706_CR20","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/jac\/dky162","volume":"73","author":"S Jacobsson","year":"2018","unstructured":"Jacobsson S, Golparian D, Scangarella-Oman N, Unemo M. In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae. J Antimicrob Chemother. 2018;73:2072\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"706_CR21","doi-asserted-by":"crossref","unstructured":"Scangarella-Oman N, Hossain M, Tiemeyer TJ Jr, et\u00a0al. Microbiological analysis from a phase IIa study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urinary tract infections. In: IDWeek 2019; 2019 October 2\u20136. Washington DC, USA.","DOI":"10.1093\/ofid\/ofz360.1346"},{"key":"706_CR22","doi-asserted-by":"publisher","first-page":"e00086","DOI":"10.1128\/AAC.00086-19","volume":"63","author":"JL Hoover","year":"2019","unstructured":"Hoover JL, Singley CM, Elefante P, Rittenhouse S. Efficacy of human exposures of gepotidacin (GSK2140944) against Escherichia coli in a rat pyelonephritis model. Antimicrob Agents Chemother. 2019;63:e00086-e119.","journal-title":"Antimicrob Agents Chemother"},{"key":"706_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00122-21","volume":"65","author":"BD VanScoy","year":"2021","unstructured":"VanScoy BD, Lakota EA, Conde H, et\u00a0al. Gepotidacin pharmacokinetics-pharmacodynamics against Escherichia coli in the one-compartment and hollow-fiber in vitro infection model systems. Antimicrob Agents Chemother. 2021;65: e0012221.","journal-title":"Antimicrob Agents Chemother"},{"key":"706_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01492-21","volume":"66","author":"NE Scangarella-Oman","year":"2022","unstructured":"Scangarella-Oman NE, Hossain M, Hoover JL, et\u00a0al. Dose selection for phase III clinical evaluation of gepotidacin (GSK2140944) in the treatment of uncomplicated urinary tract infections. Antimicrob Agents Chemother. 2022;66: e0149221.","journal-title":"Antimicrob Agents Chemother"},{"key":"706_CR25","doi-asserted-by":"publisher","first-page":"e00199","DOI":"10.1128\/AAC.00199-20","volume":"64","author":"JS Overcash","year":"2020","unstructured":"Overcash JS, Tiffany CA, Scangarella-Oman NE, et\u00a0al. Phase 2a pharmacokinetic, safety, and exploratory efficacy evaluation of oral gepotidacin (GSK2140944) in female participants with uncomplicated urinary tract infection (acute uncomplicated cystitis). Antimicrob Agents Chemother. 2020;64:e00199-e220.","journal-title":"Antimicrob Agents Chemother"},{"key":"706_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01263-21","volume":"66","author":"A Barth","year":"2021","unstructured":"Barth A, Hossain M, Brimhall DB, et\u00a0al. Pharmacokinetics of oral formulations of gepotidacin (GSK2140944), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, in healthy adult and adolescent participants. Antimicrob Agents Chemother. 2021;66: e0126321.","journal-title":"Antimicrob Agents Chemother"},{"key":"706_CR27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/cpdd.913","volume":"10","author":"M Hossain","year":"2021","unstructured":"Hossain M, Tiffany C, Tao Y, et\u00a0al. Pharmacokinetics of gepotidacin in subjects with normal hepatic function and hepatic impairment. Clin Pharmacol Drug Devel. 2021;10:588\u201397.","journal-title":"Clin Pharmacol Drug Devel"},{"key":"706_CR28","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/cpdd.807","volume":"9","author":"M Hossain","year":"2020","unstructured":"Hossain M, Tiffany C, Raychaudhuri A, et\u00a0al. Pharmacokinetics of gepotidacin in renal impairment. Clin Pharmacol Drug Devel. 2020;9:560\u201372.","journal-title":"Clin Pharmacol Drug Devel"},{"key":"706_CR29","first-page":"e02095","volume":"61","author":"W O\u2019Riordan","year":"2017","unstructured":"O\u2019Riordan W, Tiffany C, Scangarella-Oman N, et\u00a0al. Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed Gram-positive acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2017;61:e02095-e2116.","journal-title":"Antimicrob Agents Chemother"},{"key":"706_CR30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/cid\/ciy145","volume":"67","author":"SN Taylor","year":"2018","unstructured":"Taylor SN, Morris DH, Avery AK, et\u00a0al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis. 2018;67:504\u201312.","journal-title":"Clin Infect Dis"},{"key":"706_CR31","doi-asserted-by":"publisher","first-page":"e02385","DOI":"10.1128\/AAC.02385-16","volume":"61","author":"M Hossain","year":"2017","unstructured":"Hossain M, Zhou M, Tiffany C, Dumont E, Darpo B. A phase I, randomized, double-blinded, placebo- and moxifloxacin-controlled, four-period crossover study to evaluate the effect of gepotidacin on cardiac conduction as assessed by 12-lead electrocardiogram in healthy volunteers. Antimicrob Agents Chemother. 2017;61:e02385-e2416.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"706_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3109\/00498254.2015.1112933","volume":"46","author":"K Negash","year":"2016","unstructured":"Negash K, Andonian C, Felgate C, et\u00a0al. The metabolism and disposition of GSK2140944 in healthy human subjects. Xenobiotica. 2016;46(8):683\u2013702.","journal-title":"Xenobiotica"},{"key":"706_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13359","author":"C Tiffany","year":"2022","unstructured":"Tiffany C, Dumont EF, Hossain M, et\u00a0al. Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects. Clin Transl Sci. 2022. https:\/\/doi.org\/10.1111\/cts.13359.","journal-title":"Clin Transl Sci"},{"key":"706_CR34","unstructured":"Tiffany CA, Hossain M, McDonald M, Dumont EF. Effect of food on safety, tolerability and pharmacokinetics in healthy volunteers >65 years following multiple doses of GSK2140944, a novel bacterial topoisomerase inhibitor. In: 55th Interscience conference of antimicrobial agents and chemotherapy; 2015 September 17\u201321. San Diego, CA, USA."},{"key":"706_CR35","volume-title":"Adult toxicity table","author":"US National Institute for Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","year":"2007","unstructured":"US National Institute for Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases. Adult toxicity table. Bethesda: US Department of Health and Human Services; 2007."},{"key":"706_CR36","volume-title":"Pediatric Toxicity Table","author":"US National Institute for Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","year":"2007","unstructured":"US National Institute for Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases. Pediatric Toxicity Table. Bethesda: US Department of Health and Human Services; 2007."},{"key":"706_CR37","unstructured":"U.S. Food and Drug Administration. Non-Inferiority Clinical Trials to Establish Effectiveness. Guidance for Industry. 2016. https:\/\/www.fda.gov\/media\/78504\/download. Accessed 2 Aug 2022."},{"key":"706_CR38","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/00365540110080728","volume":"34","author":"LE Nicolle","year":"2002","unstructured":"Nicolle LE, Madsen KS, Debeeck GO, et\u00a0al. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis. 2002;34:487\u201392.","journal-title":"Scand J Infect Dis"},{"key":"706_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h6544","volume":"351","author":"I G\u00e1gyor","year":"2015","unstructured":"G\u00e1gyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ. 2015;351: h6544.","journal-title":"BMJ"},{"key":"706_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002569","volume":"15","author":"I Vik","year":"2018","unstructured":"Vik I, Bollestad M, Grude N, et\u00a0al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women\u2014a double-blind, randomized non-inferiority trial. PLOS Med. 2018;15: e1002569.","journal-title":"PLOS Med"},{"key":"706_CR41","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1128\/AAC.02897-15","volume":"60","author":"GV Sanchez","year":"2016","unstructured":"Sanchez GV, Babiker A, Master RN, Luu T, Mathur A, Bordon J. Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother. 2016;60:2680\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"706_CR42","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1017\/ice.2019.247","volume":"40","author":"ME Yarrington","year":"2019","unstructured":"Yarrington ME, Anderson DJ, Dodds Ashley E, et\u00a0al. Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals. Infect Control Hosp Epidemiol. 2019;40:1297\u2013300.","journal-title":"Infect Control Hosp Epidemiol"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00706-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-022-00706-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00706-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T01:33:38Z","timestamp":1677634418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-022-00706-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1007\/s40121-022-00706-9","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"15 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A peer-reviewed video abstract was retrospectively added to this publication.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}